Multiple human prolactin receptors and signaling

African Journal of Biotechnology

Volumn 9, Issue 7, 2010, Pages 940-949

  Ding, Wei ^a   Wu, Wei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Intron retention; Prolactin receptor; Signaling pathways

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROLACTIN RECEPTOR; PROTEIN P21;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; CANCER CELL; CHROMOSOME 5; GENE DELETION; GENE INTERACTION; GENE LOCATION; GENE STRUCTURE; GENETIC LINKAGE; HUMAN; INTRON; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE ANALYSIS;

EID: 77249119351     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: 10.5897/ajb09.069     Document Type: Review

References (51)

1. Ben-Jonathan N, LaPensee CR, LaPensee EW (2008). What can we learn from rodents about prolactin in humans? Endocr. Rev. 29: 1-41.
2. Goffin V, Bernichtein S, Touraine P, Kelly PA (2005). Development and potential clinical uses of human prolactin receptor antagonist. Endocr. Rev. 26: 400-422.
3. Teilum K, Hoch JC, Goffin V Kinet S, Martial JA, Kragelund BB (2005). Solution structure of human prolactin. J. Mol. Biol. 351: 810-823.
4. Davis JA, Linzer DIH (1989). Expression of multiple forms of the prolactin receptor in mouse liver. Mol. Endocrinol. 3: 674-680.
5. Boutin JM, Edery M, Shirota M Jolicoeur C, Lesueur L, Ali S, Gould D, Djiane J, Kelly PA (1989). Identification of a cDNA encoding a long form of prolactin receptor in human hepatoma and breast cancer cells. Mol. Endocrinol. 3: 1455-1461.
6. Kline JB, Roehrs H, Clevenger CV (1999). Functional characterization of the intermediate isoform of the human prolactin receptor. J. Biol. Chem. 274: 35461-35468.
7. Kline JB, Clevenger CV (2001). Identification and characterization of the prolactin binding protein in human serum and milk. J. Biol. Chem. 276: 24760-24766.
8. Kline JB, Rycyzyn MA, Clevenger CV (2002). Characterization of a novel and functional human prolactin receptor isoform (Delta S1 PRLR) containing only one extracellular fibronectin-like domain. Mol. Endocrinol. 16: 2310-22.
9. Trott JF, Hovey RC, Koduri S Vonderhaar BK (2003). Alternative splicing to exon 11 of human prolactin receptor gene results in multiple isoforms including a secreted prolactin binding protein. J. Mol. Endocrinol. 30: 31-47.
10. Fuh G, Wells JA (1995). Prolactin receptor antagonists that inhibit the growth of breast cancer cell lines. J. Biol. Chem. 270: 13133-13137.
11. Somers W, Ultsch M, De Vos AM Kossiakoff AA (1994). The x-ray structure of a growth hormone-prolactin receptor complex. Nature, 372: 478-481.
12. Laud K, Gourdou I, Belair L Peyrat JP, Djiane J (2000). Characterization and modulation of a prolactin receptor mRNA isoform in normal and tumoral human breast tissues. Int. J. Cancer 85: 771-776.
13. Ormandy CJ, Binart N, Helloco C Kelly PA (1998). Mouse prolactin receptor gene: genomic organization reveals alternative promoter usage and generation of isoforms via alternative 3′-exon splicing. DNA Cell Biol. 17: 761-770.
14. Hu ZZ, Meng JP, Dufau ML (2001). Isolation and characterization of two novel forms of the human prolactin receptor generated by alternative splicing of a newly identified exon 11. J. Biol. Chem. 276: 41086-41094.
15. Hu ZZ, Zhuang L, Meng JP Leondires M, Dufau ML (1999). The human prolactin receptor gene structure and alternative promoter utilization: The generic promoter hPIII and a novel human promoter hPN. J. Clin. Endocrinol. Metab. 84: 1153-1156.
16. Hu ZZ, Zhuang L, Meng JP Tsai-Morris CH, Dufau ML (2002). Complex 5′ genomic structure of the human prolactin receptor: Multiple alternative exons 1 and promoter utilization. Endocrinology, 143: 2139-2142.
17. Das R, Vonderhaar BK (1995). Transduction of prolactin (PRL) growth signal through both long and short forms of the PRL receptor. Mol. Endocrinol. 9: 1750-1759.
18. Qazi AM, Tsai-Morris C, Dufau M (2006). Ligand-independent homoand heterodimerization of human prolactin receptor variants: inhibitory action of the short forms by heterodimerization. Mol. Endocrinol. 20: 1912-1923.
19. Edens A, Talamantes F (1998). Alternative processing of growth hormone receptor transcripts. Endocr. Rev. 19: 559-82.
20. Horseman ND (2002). Prolactin receptor diversity in humans: novel isoforms suggest general principles. Trends Endocrinol. Metab. 13: 47-8.
21. Duan WR, Parmer TG, Albarracin CT Zhong L, Gibori G (1997). PRAP, a prolactin receptor associated protein: Its gene expression and regulation in the corpus luteum. Endocrinology, 138: 3216-3221.
22. Baumann G (1993). Growth hormone-binding proteins. Proc. Soc. Exp. Biol. Med. 202: 392-400.
23. Kopchick JJ, Andry JM (2000). Growth hormone (GH), GH receptor, and signal transduction. Mol. Genet. Metab. 71: 293-314.
24. Mannor DA, Winer LM, Shaw MA Baumann G (1991). Plasma growth hormone (GH)-binding proteins: Effect on GH binding to receptors and GH action. J. Clin. Endocrinol. Metab. 73: 30-34.
25. Bole-Feysot C, Goffin V, Edery M Binart N, Kelly PA (1998). Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 19: 225-268.
26. Arden KC, Boutin JM, Djiane J, Kelly PA, Cavenee WK (1990). The receptors for prolactin and growth hormone are localized in the same region of human chromosome 5. Cytogenet. Cell Genet. 53: 161-165.
27. Lee KM, Kaneko T (2006). Aida K. Prolactin and prolactin receptor expressions in a marine teleost, Takifugu rubripes. Gen. Comp. Endocrinol. 146: 318-328.
28. Lee SH, Kunz J, Lin SH, Yu-Lee LY (2007). 16-kDa prolatin inhibits endothelial cell migration by down-regulating the Ras-Tiam 1-Pak1 signaling pathway. Cancer Res. 67: 11045-53.
29. Lee SA, Haiman CA, Burtt NP, Pooler LC, Cheng I, Kolonel LN, Pike MC, Altshuler D, Hirschhorn JN, Henderson BE , Stram DO (2007). A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort. BMC Med. Genet. 8: 72
30. Higgs DR, Goodbourn SE, Lamb J Clegg JB, Weatherall DJ, Proudfoot NJ (1983). Alpha-thalassaemia caused by a polyadenylation signal mutation. Nature, 306: 398-400.
31. Peirce SK, Chen WY (2001). Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J. Endocrinol. 71: R1-R4.
32. Leav I, MerK FB, Lee KF Loda M, Mandoki M, McNeal JE, Ho SM (1999). Prolactin receptor expression in the developing human prostate and in hyperplastic dysplastic, and neoplastic lesions. Am. J. Pathol. 154: 863-870.
33. Nevalainen MT, Valve EM, Ingleton PM Nurmi M, Martikainen PM, Harkonen PL (1997). Prolactin and prolactin receptors are expressed and functioning in human prostate. J. Clin. Invest. 99: 618-627.
34. Ling C, Svensson L, Oden B Weijdegard B, Eden B, Dden S, Billing H (2003). Identification of functional prolactin (PRL) receptor gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J. Clin. Endocrinol. Metab. 88: 1804-1808.
35. Otte JM, Otte C, Beckedorf S Schmitz F, Vonderhaar BK, Folsch UR, Kloehn S, Herzig KH, Monig H (2002). Expression of functional prolactin and its receptor in human colorectal cancer. Int. J. Colorectal. Dis. 18: 86-94.
36. Skiyama SK (1996). Integrins in cell adhesion and signaling. Hum. Cell, 9: 181-186
37. Gadd SL, Clevenger CV (2006). Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol. Endocrinol. 20: 2734-2746.
38. Halperin J, Devi SY, Elizur S Stocco C, Shehu A, Rebourcet D, Unterman TG, Leslie ND, Le J, Binart N, Gibori G (2008). Prolactin signaling through the short form of its receptor represses forkhead transcription factor FOXO3 and its target gene galt causing a severe ovarian defect. Mol. Endocrinol. 22: 513-22.
39. Wu W, Ginsburg E, Vonderhaar Bk, Walker AM (2005). S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res. 65: 7509-15.
40. Wu W, Coss D, Lorenson MY, Kuo CB,Kuo CB, Xu XL, Walker AM (2003). Differential biological effects of unmodified prolactin and a molecular mimic of phosphorylated prolactin involve different signaling pathways. Biochemistry, 42: 7561-7570.
41. Meng JP, Tsai-Morris C, Dufau M (2004). Human prolactin receptor variants in breast cancer: low ratio of short forms to the long-form prolactin receptor associated with mammary carcinoma. Cancer Res. 64: 5677-5682.
42. Mukherjee P, Mastro AM, Hymer WC (1990). Prolactin induction of interleukin -2 receptors on rat splenic lymphocytes. Endocrinology, 126: 88-94.
43. LaVoie HA, Witorsch RJ (1995). Investigation of intracellular signals medicating the anti-apoptotic action of prolactin in Nb2 lymphoma cells. Proc. Soc. Exp. Biol. Med. 209: 257-259.
44. Yu-Lee LY, Hrachovy JA, Stevens AM M, Schwarz LA (1990). Interferon-regulatory factor-1 is an immediate-early gene under transcriptional regulation by prolactin in Nb2 T cells. Mol. Cell. Biol. 10: 3087-3094.
45. Clevenger CV, Torigoe T, Reed JC (1994). Prolactin induces rapid phosphorylation and activation of prolactin receptor associated Raf-1 kinase in a T-cell line. J. Biol. Chem. 269: 5559-5565.
46. Clevenger CV, Sillman AL, Hanley-Hyde J, Prystowsky MB (1992). Requirement for prolactin during cell cycle regulated gene expression in cloned T-lymphocytes. Endocrinology, 130: 3216-3222.
47. Ali S, Ali S (2000). ecruitment of the protein-tyrosine phosphatase SHP-2 to the C-terminal tyrosine of the prolactin receptor and to the adaptor protein Gab2. J. Biol. Chem. 39073-39080.
48. Matsushita N, Kato Y, Shimatsu A Katakami H, Yanaihara N, Imura H (1983). Effects of VIP, TRH, GABA and dompamine on prolactin release from superfused rat anterior pituitary cells. Life Sci. 32: 1263-1269.
49. Cella N, Groner B, Hynes NE (1998). Characterization of Stat5a and Stat 5b homodimers and heterodimers and their association with the glucocorticoid receptor in mammary cells. Mol. Cell. Biol. 18: 1783-1792.
50. Ukkola O, Perusse L, Chagnon YC Despres JP, Bouchard C (2001). Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Quebec family study. Int. J. Obes. 25: 1332-1339.
51. Yang QH, Khoury MJ, Sun FZ Flanders WD (1999). Case-only design to measure gene-gene interaction. Epidemiology, 10: 167-170.